Merck's earnings call highlighted significant concerns, including reduced guidance for key products like GARDASIL and SINGULAIR, and uncertainty due to the SEAS study impacting ZETIA and VYTORIN. The inability to provide updated EPS guidance and the decrease in equity income suggest the stock will face substantial short-term pressure.

[-2]